查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1596655

特种非专利市场：按类型、应用和最终用途 - 2025-2030 年全球预测

Specialty Generics Market by Type (Injectables, Oral Drugs), Application (Hepatitis C, Inflammatory Conditions, Multiple Sclerosis), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，特种非专利市场价值为848.6亿美元，预计到2024年将达到935.6亿美元，复合年增长率为10.73%，到2030年将达到1732.5亿美元。

特种非专利市场包括多种特种药物的学名药。与传统学名药不同，这些药物涉及复杂的製造流程、专有配方和分销管道，并针对癌症、自体免疫疾病和中枢神经神经病变等利基治疗领域。对特种非专利的需求源于其在保持治疗效果的同时显着降低医疗成本的潜力，这对于慢性和危及生命的疾病的管理尤其重要。应用范围广泛，主要关注学名药竞争有限的治疗方法。最终用途包括需要经济有效的治疗方案的医院、诊所和专业药局。

主要市场统计
基准年[2023] 848.6亿美元
预测年份 [2024] 935.6亿美元
预测年份 [2030] 1732.5亿美元
复合年增长率（%） 10.73%

影响该市场的主要成长要素包括慢性病盛行率上升、药品价格上涨以及对具有成本效益的替代疗法的需求不断增加。重磅药物的专利到期也为特种非专利製造商创造了利润丰厚的机会。药物输送系统和製剂技术的技术创新也支持市场扩张。但也存在着监管严格、市场开拓和製造流程高成本挑战。来自品牌专科药物的竞争也很激烈，使新参与企业的市场进入更加复杂。

为了利用新的商机，公司应该专注于生物相似药。生物相似药正在迅速获得接受，并成为政策辩论中具有影响力的推动者。对奈米製剂和长效注射剂等创新给药方法的先进研究和开发的投资可以提供竞争优势。扩大分销和行销方面的策略伙伴关係将加强市场渗透。了解区域市场动态，特别是新兴经济体的市场动态，将有助于开拓服务不足但潜力巨大的地区。然而，市场仍然受到高度监管，不断变化的有关智慧财产权和定价策略的法律法规需要灵活的反应和策略规划。因此，持续监控监管状况和竞争对手的行为至关重要。在竞争激烈且开拓的专业市场中，创新和策略远见至关重要。

市场动态：揭示快速发展的特种非专利市场的关键市场洞察

供需的动态交互作用正在改变特种非专利市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 扩大特殊学名药在复杂慢性病治疗的应用
    • 是否有新产品核准的监理支援政策
    • 药物研发的重大投资
  • 市场限制因素
    • 与特种非专利相关的高成本
  • 市场机会
    • 先进医疗企业的出现和研发项目的快速增加
    • 患者人数众多，对廉价医疗设施的需求不断增长
  • 市场挑战
    • 对开发和销售成本的担忧

波特的五力：驾驭特种非专利市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解专业非专利市场的外部影响

外部宏观环境因素在塑造特种非专利市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解专业非专利市场的竞争状况

对特种非专利市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵专业非专利市场供应商的绩效评估

FPNV 定位矩阵是评估特种非专利市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议 规划特种非专利市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，特种非专利市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告提供了涵盖关键重点领域的市场全面分析：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 越来越多地采用专业学名药来治疗复杂的慢性病
      • 是否有新产品核准的支持性监理政策
      • 药物研发的大量投资
    • 抑制因素
      • 与特种非专利相关的高成本
    • 机会
      • 存在先进的医学公司和快速增加的研发项目
      • 患者数量不断增加，对负担得起的医疗设施的需求不断增加
    • 任务
      • 对开发和行销成本的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 专业非专利市场：依类型

  • 注射
  • 口腔医学

第七章 专业非专利市场：依应用分类

  • C型肝炎
  • 发炎疾病
  • 多发性硬化症
  • 肿瘤学

第八章 特种非专利市场：依最终用途

  • 医院药房
  • 零售药房
  • 专业药房

第九章 美洲的特殊非专利市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章 亚太地区特殊非专利市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的特殊非专利市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Akorn Operating Company LLC
  • Apotex Inc.
  • Aspen Group
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • Fresenius Kabi AG
  • Generic Specialties, Inc.
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Group
Product Code: MRR-205091A88B67

The Specialty Generics Market was valued at USD 84.86 billion in 2023, expected to reach USD 93.56 billion in 2024, and is projected to grow at a CAGR of 10.73%, to USD 173.25 billion by 2030.

The Specialty Generics market encompasses a range of generic versions of specialty pharmaceuticals. Unlike traditional generics, these drugs involve complex manufacturing processes, unique formulations, and distribution channels, serving niche therapeutic areas such as oncology, autoimmune diseases, and central nervous system disorders. The necessity of specialty generics stems from their potential to drastically reduce healthcare costs while maintaining treatment efficacy, which is particularly crucial in managing chronic or life-threatening conditions. Applications span multiple uses, primarily focusing on therapies with limited generic competition. End-use extends to hospitals, clinics, and specialty pharmacies that require cost-effective treatment options.

KEY MARKET STATISTICS
Base Year [2023] USD 84.86 billion
Estimated Year [2024] USD 93.56 billion
Forecast Year [2030] USD 173.25 billion
CAGR (%) 10.73%

Key growth factors influencing this market include the rising incidence of chronic diseases, escalating drug prices, and increasing demand for cost-efficient treatment alternatives. In addition, patent expirations of blockbuster drugs present lucrative opportunities for specialty generics manufacturers. Technological innovations in drug-delivery systems and formulation techniques also bolster market expansion. However, the market encounters challenges such as stringent regulatory scrutiny and the high cost of development and manufacturing processes. There is significant competition from branded specialty drugs, further complicating market entry for new players.

To capitalize on emerging opportunities, companies should focus on biosimilars, which are rapidly gaining acceptance and gaining influential traction in policy discussions. Investing in advanced R&D for innovative delivery methods, such as nano-formulations and long-acting injectables, can provide competitive advantages. Expanding strategic partnerships for distribution and marketing would enhance market penetration. Understanding regional market dynamics, especially in emerging economies, will aid in exploiting under-served yet high-potential areas. However, the market remains tightly regulated, and evolving legislation regarding intellectual property and pricing strategies demands agile responses and strategic planning. Thus, continuous monitoring of regulatory landscapes and competitor actions is imperative. The specialties' market landscape is competitive yet ripe with untapped potential, requiring innovation and strategic foresight for successful navigation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Specialty Generics Market

The Specialty Generics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing adoption of specialty generic medicines for the treatment of complex chronic diseases
    • Presence of supportive regulatory policies regarding the approval of new products
    • Significant investments for drug development
  • Market Restraints
    • High costs associated with specialty generics
  • Market Opportunities
    • Availability of medically advanced companies and proliferating research & development programs
    • High patient population and growing demand for affordable healthcare facilities
  • Market Challenges
    • Concerns regarding development and marketing costs

Porter's Five Forces: A Strategic Tool for Navigating the Specialty Generics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Specialty Generics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Specialty Generics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Specialty Generics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Specialty Generics Market

A detailed market share analysis in the Specialty Generics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Specialty Generics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Specialty Generics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Specialty Generics Market

A strategic analysis of the Specialty Generics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Specialty Generics Market, highlighting leading vendors and their innovative profiles. These include Akorn Operating Company LLC, Apotex Inc., Aspen Group, Aurobindo Pharma Limited, Bausch Health Companies Inc., Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International plc, Fresenius Kabi AG, Generic Specialties, Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Mallinckrodt Pharmaceuticals, Novartis AG, Pfizer Inc., STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Specialty Generics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Injectables and Oral Drugs.
  • Based on Application, market is studied across Hepatitis C, Inflammatory Conditions, Multiple Sclerosis, and Oncology.
  • Based on End-Use, market is studied across Hospital Pharmacy, Retail Pharmacy, and Specialty Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing adoption of specialty generic medicines for the treatment of complex chronic diseases
      • 5.1.1.2. Presence of supportive regulatory policies regarding the approval of new products
      • 5.1.1.3. Significant investments for drug development
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with specialty generics
    • 5.1.3. Opportunities
      • 5.1.3.1. Availability of medically advanced companies and proliferating research & development programs
      • 5.1.3.2. High patient population and growing demand for affordable healthcare facilities
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns regarding development and marketing costs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Specialty Generics Market, by Type

  • 6.1. Introduction
  • 6.2. Injectables
  • 6.3. Oral Drugs

7. Specialty Generics Market, by Application

  • 7.1. Introduction
  • 7.2. Hepatitis C
  • 7.3. Inflammatory Conditions
  • 7.4. Multiple Sclerosis
  • 7.5. Oncology

8. Specialty Generics Market, by End-Use

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Retail Pharmacy
  • 8.4. Specialty Pharmacy

9. Americas Specialty Generics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Specialty Generics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Specialty Generics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Akorn Operating Company LLC
  • 2. Apotex Inc.
  • 3. Aspen Group
  • 4. Aurobindo Pharma Limited
  • 5. Bausch Health Companies Inc.
  • 6. Cipla Limited
  • 7. Dr. Reddy's Laboratories Ltd.
  • 8. Endo International plc
  • 9. Fresenius Kabi AG
  • 10. Generic Specialties, Inc.
  • 11. Hikma Pharmaceuticals PLC
  • 12. Lupin Limited
  • 13. Mallinckrodt Pharmaceuticals
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. STADA Arzneimittel AG
  • 17. Sun Pharmaceutical Industries Ltd.
  • 18. Teva Pharmaceutical Industries Ltd.
  • 19. Viatris Inc.
  • 20. Zydus Group

LIST OF FIGURES

  • FIGURE 1. SPECIALTY GENERICS MARKET RESEARCH PROCESS
  • FIGURE 2. SPECIALTY GENERICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SPECIALTY GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. SPECIALTY GENERICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. SPECIALTY GENERICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SPECIALTY GENERICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SPECIALTY GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SPECIALTY GENERICS MARKET DYNAMICS
  • TABLE 7. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INFLAMMATORY CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 146. SPECIALTY GENERICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. SPECIALTY GENERICS MARKET, FPNV POSITIONING MATRIX, 2023